Extracellular vesicles (EVs) are lipid-membrane bound, cell-derived nanoparticles secreted by all cell types under physiological and pathological conditions. They are found in most biological fluids including plasma, serum, urine, saliva, and cerebrospinal fluid (CSF). EV transport packages of proteins, lipids, and nucleic acids including microRNAs that reflect the physiological state of their cell of origin. As a result, EVs have emerged as powerful vehicles for biomarker discovery and liquid biopsy.
However, isolating EVs in a form compatible with downstream next-generation sequencing (NGS), particularly for small RNA analysis, remains a significant technical challenge. In this review, we list and evaluate major EV isolation techniques, their application to various biofluids, and their compatibility with small RNA NGS.
Ultracentrifugation (UC)
UC is a traditional method involving sequential centrifugation steps to remove cells and debris before pelleting EVs at ~100,000 x g. UC remains widely used for cell culture media and CSF. Jeppesen et al.¹ demonstrated successful recovery of EVs for small RNA-seq from CSF using this approach.
Input volume: 5-50 mL of biofluid or culture supernatant
Typical yield: ~10⁸–10⁹ EV particles; ~50–200 ng RNA.
Density gradient centrifugation
Layering a sucrose or iodixanol density gradient post-UC enhances purity. Thery et al.² and Buschmann et al.³ applied this method successfully to plasma and urine samples, resulting in high-quality small RNA profiles.
Input volume: ~1–5 mL of plasma or urine.
Typical yield: ~10⁸ EV particles; ~50–150 ng RNA.
Size exclusion chromatography (SEC)
SEC separates EVs by size using porous resin-packed columns. It preserves EV structure and efficiently separates them from soluble proteins. Monguió-Tortajada et al.4 showed excellent miRNA profiling from plasma using qEV columns. Exo-spin™ kits from Cell Guidance Systems5, which combine precipitation and SEC, have been used in hundreds of EV studies and have shown consistent results in plasma and CSF for small RNA profiling.
Input volume: 0.5–1 mL of plasma/serum; up to 5 mL of CSF.
Typical yield: ~10⁹ EV particles; 20–100 ng RNA.
Precipitation-based methods
Polymer-based kits like ExoQuick® offer simplicity and speed but co-purify large amounts of non-exosomal proteins and other material, as well as carried-over precipitant. Yang et al.⁶ found significant biases in small RNA profiles from plasma and urine using precipitation. Wei et al.7 successfully used this approach on saliva, though with noted variability.
Input volume: 0.5–1 mL of biofluid
Typical yield: ~108 EVs (variable count); 50–200 ng RNA.
Ultrafiltration and Tangential Flow Filtration (TFF)
These membrane-based approaches concentrate and purify EVs by size. Li et al.8 showed that TFF can isolate intact EVs from large volumes of urine, yielding clean small RNA suitable for sequencing.
Input volume: 10–100 mL of urine or conditioned media
Typical yield: ~109–1010 EV particles; 200–500 ng RNA.
Immunoaffinity captur
Using antibodies against EV surface proteins (CD63, CD9, CD81), this method enables highly specific capture. Greening et al.9 applied this strategy to enrich serum EVs for disease-relevant miRNAs.
Input volume: 0.1–0.5 mL of biofluid
Typical yield: ~107–108 EV particles; 10–50 ng RNA.
Microfluidic platforms
Emerging microfluidic devices allow EV capture from small sample volumes with minimal processing. Smith et al.10 and Wei et al.7 demonstrated improved consistency and small RNA yield from plasma and saliva, respectively.
Input volume: 10–200 μL of biofluid
Typical yield: ~106–107 EV particles; 5–20 ng RNA.
Acoustic and dielectrophoretic separation
These label-free techniques separate EVs using acoustic waves or electric fields. Wu et al.11 used this approach to isolate EVs from whole blood, preserving their native RNA cargo.
Input volume: 0.5–2 mL of whole blood
Typical yield: ~108 EV particles; 50–150 ng RNA.
Method | Benefits | Limitations | Best fluids |
---|---|---|---|
Ultracentrifugation | High recovery; low cost | Contaminants; laborious | Cell culture, CSF |
Density gradient centrifugation | High purity; consistent RNA yield | Low throughput | Plasma, urine |
Size exclusion chromatography | Preserves integrity; reproducible; High RNA quality | Requires EV concentration (unless combined with precipitation) | Plasma, serum, CSF |
Precipitation-based methods | Simple; no special equipment | Contamination; RNA profile distortion | Saliva |
Ultrafiltration / TFF | Scalable; gentle processing | May lose smallest EVs | Urine |
Immunoaffinity capture | High specificity; isolates disease-relevant subtypes | Costly; biased to markers used | Serum, CSF |
Microfluidic platforms | Minimal volume; automatable | Still developing; low throughput | Saliva, serum |
Acoustic/Dielectrophoretic | Label-free; preserves native state | Specialized setup; not clinical-ready | Whole blood |
Table 1. Summary of EV isolation methods
Future developments
The ability to isolate and characterize EV subpopulations based on their protein composition is driving the next wave of innovations. Platforms like NanoView utilize interferometric imaging and fluorescent tagging to detect and phenotype individual EVs. ExoView further extends this concept by immobilizing EVs on chip surfaces with antibody capture, enabling multiplexed analysis of surface markers and associated RNA content. Immunomagnetic Capture with barcoded beads and mass cytometry is enabling scalable, high-specificity isolation workflows. These advances will make it possible to integrate EV surface profiling with transcriptomic data at the single-vesicle level, which can be a game-changer for mechanistic studies.
Conclusion
No one-size-fits-all approach exists for EV isolation. Method selection must consider sample type, throughput needs, and the analytical endpoint. For small RNA sequencing , SEC-based kits like Exo-spin™, density gradients, and immunoaffinity methods offer the highest purity. Continued advances in isolation specificity, especially through protein marker-based subpopulation sorting, will open new frontiers in functional EV genomics.
References:
- Jeppesen DK. et al. (2023) "Re-evaluating the role of EVs in RNA biomarker research." Nat Cell Biol 25(1):1–13.
- Thery C. et al. (2023) "Minimal information for studies of extracellular vesicles 2023 (MISEV2023)." J Extracell Vesicles 12(4):e12350.
- Buschmann D. et al. (2023) "Evaluation of serum exosome isolation methods for profiling miRNAs by next-generation sequencing." J Circ Biomark 12:1–13.
- Monguió-Tortajada M. et al. (2023) "Extracellular vesicle isolation methods: Promises and pitfalls." Nat Rev Mol Cell Biol 24(2):101–114.
- Cell Guidance Systems (2024) "Exo-spin Technology Overview and Performance Data." White Paper.
- Yang D. et al. (2023) "Comparative analysis of EV isolation methods from human plasma for RNA sequencing." Anal Biochem 668:115013.
- Wei Z. et al. (2023) "Comparison of EV isolation methods from human saliva for small RNA sequencing." Clin Chem Lab Med 61(8):1520–1529.
- Li M. et al. (2024) "Microfluidic technologies for EV isolation and analysis." Biosens Bioelectron 229:115238.
- Greening DW. et al. (2023) "EV subpopulation separation: Proteomic profiling and functional implications." Proteomics 23(5):e2200312.
- Smith HL. et al. (2023) "Next-generation profiling of small RNAs in EVs: technical considerations and applications." RNA Biol 20(1):57–69.
- Wu Y. et al. (2024) "Surface marker-based isolation of EV subtypes using magnetic nanoparticles." ACS Nano 18(1):220–234.
For research use only. Not for use in diagnostic procedures.